MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy

Press release content from Accesswire. The AP news staff was not involved in its creation.

Related Keywords

China ,Germany ,Japan ,United States ,Munich ,Bayern ,Planegg ,America ,American ,Semin Nephrol ,Thomas Biegi ,Julia Neugebauer ,Asia Pacific ,Myles Clouston ,Mikhail Akimov ,Jeanette Bressi ,Global Head Drug Development At Morphosys ,Janssen Biotech Inc ,Drug Administration ,Single Center ,Morphosys Group ,Constellation Pharmaceuticals Inc ,Janssen Research Development ,Morphosys Us Inc ,Distribution Services ,Exchange Commission ,Us Communications ,Senior Vice President ,Global Head Drug Development ,North America ,I Mab Biopharma ,Janssen Research ,Janssen Biotech ,Constellation Pharmaceuticals ,Morphosy Annual Report ,Res Clin ,Iga Nephropathy ,Clinj Am Soc ,Containing Immune Complexes ,Year Analysis ,Corporate News ,Regulatory Announcements ,Business ,Health ,Accesswire ,Clinical Trials ,Morphosys Ag ,